Sydney Lupkin
From this contributor
Pharma spending on lobbying skyrocketed in Trump’s first quarter
Eight pharmaceutical companies more than doubled their lobbying spending in the first three months of 2017.
Pharma spending on lobbying skyrocketed in Trump’s first quarter
Health companies gave generously to President Trump’s inauguration
Facing acute risks to their businesses from Washington policymakers, health companies spent more than $2 million to buy access to the incoming Trump administration via candlelight dinners, black-tie balls and other inauguration events.
Health companies gave generously to President Trump’s inauguration
Trump’s choice to run food and drug agency has pharma connections
Scott Gottlieb, nominated to lead the U.S. Food and Drug Administration has deep ties to industry, and has worn many other hats in his career.
Trump’s choice to run food and drug agency has pharma connections
Senators call for investigation into possible abuses of Orphan Drug Act
Building on weeks of mounting pressure to address high prescription drug prices, three influential U.S. senators have asked the government’s accountability arm to probe the orphan drug program for potential misuse.
Senators call for investigation into possible abuses of Orphan Drug Act
Former head of FDA concerned about faster drug approvals
Robert Califf, the just-departed commissioner of the U.S. Food and Drug Administration, offers his take on the Trump administration's plans to speed up drug approvals and dramatically reduce regulations at the agency.
Former head of FDA concerned about faster drug approvals
Explore more from The Transmitter
Is it time for neuroscience to shift its focus from a computational mind to a navigating mind?
Andrea Hiott explains her navigational approach to the mind, and why now is the time to embrace seemingly paradoxical findings in neuroscience.
Is it time for neuroscience to shift its focus from a computational mind to a navigating mind?
Andrea Hiott explains her navigational approach to the mind, and why now is the time to embrace seemingly paradoxical findings in neuroscience.
Human brain organoids come of age—but still have room to grow
The U.S. government has touted organoids as an alternative to animals for studying the brain. The model has improved since its debut in 2013, but scientists are still working to overcome key limitations: immaturity, consistency and the lack of vascularization.
Human brain organoids come of age—but still have room to grow
The U.S. government has touted organoids as an alternative to animals for studying the brain. The model has improved since its debut in 2013, but scientists are still working to overcome key limitations: immaturity, consistency and the lack of vascularization.
Finding neuroheterogeneity’s sweet spot
Once thought to be detrimental to memory processing, neuronal diversity—at the right ‘Goldilocks’ dose—is a new boon to theoretical neuroscience.
Finding neuroheterogeneity’s sweet spot
Once thought to be detrimental to memory processing, neuronal diversity—at the right ‘Goldilocks’ dose—is a new boon to theoretical neuroscience.